Leerink Swann Starts Heartware Int'l (HTWR) at Outperform; Positive Inflection Point Nears, Strong Growth Ahead
Tweet
Share
E-mailGet Alerts HTWR Hot Sheet
Price: $57.98 --0%
Rating Summary:
5 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
5 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Leerink Swann initiates coverage on Heartware Int'l (NASDAQ: HTWR) with an Outperform. PT $95.00.
Leerink analyst says, "In the near term, HTWR shares could be volatile as investors await greater clarity on HVAD regulatory timelines. But, over the next 12 months, we think HTWR shares should move higher driven by: 1) regulatory milestones, including an FDA panel and ultimate HVAD approval; 2) incremental data updates that should further mitigate HVAD thrombus concerns; 3) rapid BTT market share gains that should help drive 50%+ 2013 sales growth---over 2x the current average projected growth rate for comparable small-cap MedTech companies; and 4) further pipeline progress, including first-inman clinical trials for the next-gen MVAD, expected to begin in 1H12."
For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.
Shares of Heartware Int'l closed at $67.31 yesterday.
Leerink analyst says, "In the near term, HTWR shares could be volatile as investors await greater clarity on HVAD regulatory timelines. But, over the next 12 months, we think HTWR shares should move higher driven by: 1) regulatory milestones, including an FDA panel and ultimate HVAD approval; 2) incremental data updates that should further mitigate HVAD thrombus concerns; 3) rapid BTT market share gains that should help drive 50%+ 2013 sales growth---over 2x the current average projected growth rate for comparable small-cap MedTech companies; and 4) further pipeline progress, including first-inman clinical trials for the next-gen MVAD, expected to begin in 1H12."
For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.
Shares of Heartware Int'l closed at $67.31 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- Canaccord Starts Galiano Gold (GAU:CN) at Buy
- Evercore ISI Starts Alvotech SA (ALVO) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
